Estimating the Effect of Coronavirus Disease 2019 (COVID-19) Vaccination and Infection Variant on Post-COVID-19 Venous Thrombosis or Embolism Risk

Abstract Background Previous research has shown that vaccination reduces risk of post–coronavirus disease 2019 (COVID-19) venous thrombosis or embolism (VTE), but the effect of vaccine boosting on post-COVID-19 VTE risk reduction is unclear. We sought to estimate the effect of COVID-19 vaccination o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open Forum Infectious Diseases 2024-11, Vol.11 (11), p.ofae557
Hauptverfasser: O’Carroll, Andrew, Richard, Stephanie A, Byrne, Celia, Rusiecki, Jennifer, Wier, Ben, Berjohn, Catherine M, Fries, Anthony C, Lalani, Tahaniyat, Smith, Alfred G, Mody, Rupal M, Ganesan, Anuradha, Huprikar, Nikhil, Colombo, Rhonda E, Schofield, Christina, Lindholm, David A, Mende, Katrin, Jones, Milissa U, Flanagan, Ryan, Larson, Derek T, Ewers, Evan C, Saunders, David, Maves, Ryan C, Maldonado, Carlos J, Sanchez Edwards, Margaret, O’Connell, Robert J, Simons, Mark P, Tribble, David R, Agan, Brian K, Burgess, Timothy H, Pollett, Simon D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Previous research has shown that vaccination reduces risk of post–coronavirus disease 2019 (COVID-19) venous thrombosis or embolism (VTE), but the effect of vaccine boosting on post-COVID-19 VTE risk reduction is unclear. We sought to estimate the effect of COVID-19 vaccination on the risk of post-COVID-19 VTE and to examine if the magnitude of this association differed among variant eras. Methods We performed a case-control study of Military Health System (MHS) beneficiaries who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2020–2022. Cases were defined as those with medically attended VTE within 90 days after their first positive SARS-CoV-2 test; controls were defined as SARS-CoV-2 infections without incident VTE by 90 days. Multivariate logistic regression estimated the odds of post-SARS-CoV-2 VTE based on pre-COVID-19 vaccine status, adjusting for other VTE risk factors. Results A total of 4646 MHS beneficiaries were included in this analysis; 1370 received a primary vaccine series and a further 790 received at least 1 booster at time of infection; 71 had VTE within 90 days of SARS-CoV-2 infection. Those who were vaccinated had lower odds of VTE (adjusted odds ratio [95% confidence interval]) compared to the unvaccinated following infection (primary series: 0.28 [.13–.62]; booster dose: 0.06 [.01–.46]). Post-COVID-19 VTE risk was lowest during the Omicron era, but VTEs were too rare to examine for an interaction of variant era and vaccine effect. Conclusions Among MHS beneficiaries, COVID-19 vaccination was associated with a reduced risk of post-COVID-19 VTE diagnosis; estimated risk reduction was larger among those who received a booster. Among Military Health System beneficiaries, COVID-19 vaccination was associated with a reduced risk of post-COVID-19 venous thrombosis or embolism diagnosis. The estimated risk reduction was larger among those who received a booster.
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofae557